Jiangsu Longfengtang Chinese Medicine Co., Ltd. is a wholly-owned subsidiary of Yangzijiang Pharmaceutical Group. It is a professional R&D and manufacturing enterprise of proprietary Chinese medicine. It was registered in 2013, started construction in 2014, and fully put into operation in 2018. It covers an area of 1564 mu and has 1,300 employees. Relying on the traditional Chinese medicine varieties and industry advantages accumulated by Yangzijiang Pharmaceutical Group for more than 50 years, it has built a comprehensive large-scale enterprise covering the whole industrial chain and covering the cultivation of traditional Chinese medicine, the processing of traditional Chinese medicine slices, the research and development, production, sales and logistics of proprietary Chinese medicine.

It has an annual comprehensive extraction capacity of 50,000 tons, 1 billion bags of granules, 3.2 billion tablets, 1.6 billion capsules, and 2 billion bottles of mistura (oral liquid). The company has always been committed to the inheritance of traditional Chinese medicine classic prescriptions and academic thoughts of traditional Chinese medicine practitioners. The main products are Suhuang cough capsule, Lanqin oral liquid, Weisu granule, Beiling weitong granule, Astragalus Extract, Shenqu Xiaoshi oral liquid, etc., with a stable market share, which is widely recognized by doctors and patients.

Quality control covers the whole chain of pharmaceutical and drug use, and realizes the quality traceability of the whole process of Chinese herbal medicine cultivation, decoction piece processing, patent medicine processing, finished product storage, quality detection and product flow. Chinese herbal medicine planting bases have been built in Gansu, Inner Mongolia, Shaanxi and other genuine medicinal materials producing areas, and the main varieties have realized the source localization of medicinal materials, ensuring the control of raw material sources. The modern inspection and testing Research center has been recognized by CNAS and approved by the National Development and Reform Commission as a "public service platform for Chinese Medicine Quality and safety Testing and whole-process traceability". The company continued to carry out research on the quality standards of medicinal materials, successively won 3 national Science and Technology Progress prizes in the category of proprietary Chinese medicines, undertook the research work of 15 Chinese medicinal materials "European Pharmacopoeia" plant monographs, of which 5 varieties have been successfully included in the "European Pharmacopoeia", and made pioneering contributions to the internationalization of Chinese medicine standards.

The company integrates modern scientific and technological concepts, constantly draws on the experience of various industries, pioneered the overall logistics system of traditional Chinese medicine and the robot feeding system, realized the application of the production execution system in the extraction of traditional Chinese medicine, and formed a complete set of modern traditional Chinese medicine pre-processing to extraction of the overall solution. Has completed the implementation of the Ministry of Industry and Information Technology "Chinese medicine process manufacturing smart factory new model application project" and the National Standards Commission "Chinese Medicine process intelligent manufacturing National high-tech industry standardization pilot".

With the core concept of "originality inherits the quintessence of China, innovation and health protection", Longfengtang will always resonate with "Healthy China". It will match the overall layout of "medicine, medicine, nutrition, food and tourism" integrated development of Yangzijiang Pharmaceutical Group, and explore the operation mode with Yangzijiang characteristics in the fields of R&D, production, supply chain and marketing. Strive to grow into the domestic Chinese medicine industry leader.